Inclusion Criteria:  Breast cancer patients with biopsy proven invasive cancer Clinically and radiographically node negative No indication of metastatic disease Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 Synchronous bilateral invasive cancer allowed Negative serum pregnancy test within one month from the radiation therapy (RT) boost delivery Willingness to participate in the clinical trial and adhere to the study protocol Individuals of all races, genders and ethnic groups are eligible for this trial  Exclusion Criteria:  Need for neoadjuvant chemotherapy Inflammatory breast cancer (cT4) Multicentric tumor Prior ipsilateral breast or thoracic RT Contraindication for baseline magnetic resonance imaging (MRI) Contraindication for surgery Distant metastatic disease Other synchronous cancer (besides bilateral breast) Contraindication to radiation therapy (presence of scleroderma or other collagen vascular disease) Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration, impair the ability of the subject to receive protocol therapy, or interfere with the interpretation of study results